-
Ferring Pharmaceuticals Announces Grand Opening of U.S. Operations Center
-Ferring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new U.S. Operations Center on a 25-acre lot located at 100…
-
New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists
-New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS)…
-
CORTIMENT®MMX®, a new treatment for ulcerative colitis, receives European approval
-Ferring Pharmaceuticals announced today that its CORTIMENT® MMX® (budesonide) treatment for the induction of remission in patients…
-
The Scottish Medicines Consortium (SMC) accepts MYSODELLE® for use in NHS Scotland
-Ferring Pharmaceuticals Ltd, U.K. announced today that the Scottish Medicines Consortium (SMC) has accepted its new product…
-
Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment
-Ferring Pharmaceuticals and Roche have announced a collaboration to combine diagnostic testing technology from Roche with Ferring’s human cell…
-
Ferring launches Guts4life, an interactive online resource for people with inflammatory bowel disease
-Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information…
-
New study suggests desmopressin melt improves sleep patterns and psychological functioning of bedwetting children
-New data has shown that treatment with melt-in-the-mouth desmopressin (MINIRIN® Melt)* improved sleep patterns and psychological functioning…
-
Real-world patient survey data shows negative impact of nocturia
-New patient survey data presented today at the European Association of Urology (EAU 14) congress, showed that nocturia…
-
MSD, Ferring Pharmaceuticals and the World Health Organization – Working Together to Prevent Excessive Bleeding in Women after Childbirth
-Ferring Pharmaceuticals and MSD, known as Merck in the United States and Canada, today announced their collaboration with the World Health…
-
New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists
-A paper published today in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin…
PRESS RELEASE 2014
PRESS RELEASE 2014